Vistagen CFO Jerrold D. Dotson to retire by Aug 31, 2023; successor identified

Vistagen Therapeutics, Inc.

CFO Jerrold D. Dotson intends to retire on or about August 31, 2023.
Retirement not due to any disagreement with the company on operations or policies.
Board has identified a potential successor, subject to completion of onboarding activities.
Company will announce successor upon appointment.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jerrold D. Dotson

Vice President and Chief Financial Officer

VTGN · Vistagen Therapeutics, Inc.

Effective: 2023-08-31
Filed: July 7, 2023, 7:59 PM ET

On July 7, 2023, Vistagen Therapeutics, Inc. (the “ Company ”) announced that Jerrold D. Dotson, CPA, Vice President and Chief Financial Officer (principal financial and accounting officer), intends to retire from the Company on or about August 31, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jerrold D. Dotson departed as Vice President and Chief Financial Officer at Vistagen Therapeutics, Inc..

Action: intends to retire
Role: Vice President and Chief Financial Officer

Exact text from the filing

On July 7, 2023, Vistagen Therapeutics, Inc. (the “ Company ”) announced that Jerrold D. Dotson, CPA, Vice President and Chief Financial Officer (principal financial and accounting officer), intends to retire from the Company on or about August 31, 2023.

View on SEC.gov

Vistagen Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-019610

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.